The Comprehensive Genetic Test for Long QT Syndrome (LQTS) utilizes next-generation sequencing (NGS) to examine 18 genes associated with long QT syndrome and cardiac ion channel disorders. It is a targeted gene panel specifically designed to support accurate diagnosis, risk assessment, and prevention.
More Information
The Comprehensive Genetic Test for Long QT Syndrome (LQTS) is a targeted genetic test designed to evaluate hereditary causes of long QT syndrome, a cardiac channelopathy affecting the electrical activity of the heart. The comprehensive genetic test for long qt syndrome (LQTS) includes the analysis of a set of genes, along with selected non-coding variants, enabling a comprehensive assessment of genetic factors associated with this condition. It is particularly suitable for individuals with a clinical suspicion or diagnosis of long QT syndrome. This disorder is characterized by prolonged cardiac repolarization, which may predispose to life-threatening arrhythmias in structurally normal hearts.
The comprehensive genetic test for long QT syndrome (LQTS) includes key genes such as KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2, which are involved in cardiac ion channel function and regulation of electrical signaling. These genes control the flow of potassium and sodium ions across cardiac cell membranes, which is essential for the proper timing of cardiac repolarization. Disruptions in these pathways lead to prolonged action potentials and increased susceptibility to arrhythmias. The comprehensive genetic test for long QT syndrome (LQTS) is indicated in individuals presenting with clinical or electrocardiographic features suggestive of long QT syndrome.
The clinical spectrum of long QT syndrome (LQTS) includes syncope, ventricular arrhythmias, and sudden cardiac death, often occurring in young individuals with otherwise normal cardiac structure. Symptoms may be triggered by physical exertion, emotional stress, or occur at rest. In some cases, sudden cardiac death may be the first manifestation of the condition. The disease may present from infancy through adulthood, with considerable variability in severity and clinical expression. A more severe phenotype, such as Jervell and Lange-Nielsen syndrome, may occur in association with congenital hearing loss and typically results from biallelic mutations in KCNQ1.
The purpose of the comprehensive genetic test for long QT syndrome (LQTS) is to identify pathogenic variants associated with long QT syndrome, thereby supporting accurate diagnosis and differentiation from other arrhythmia disorders. Genetic findings contribute to improved understanding of the molecular mechanisms underlying cardiac repolarization abnormalities and support appropriate disease classification. The identification of specific genetic alterations assists in risk assessment, prognosis evaluation, and the development of individualized long-term monitoring strategies.
A higher genetic risk is confirmed when pathogenic mutations are found in genes associated with long QT syndrome, including KCNQ1, KCNH2, and SCN5A. A lower risk may be inferred when no mutations are detected, though comprehensive clinical follow-up is still essential. The integration of genetic data with clinical findings and electrocardiographic evaluation is critical for precise diagnosis, prognosis, and long-term patient care.
The test is performed in a clinical laboratory accredited to ISO 15189 and certified by CLIA and CAP, ensuring the validity, accuracy and international recognition of the results.
